

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

DRAGON PHARMACEUTICAL INC
Form 8-K
May 19, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 16, 2005

DRAGON PHARMACEUTICAL INC.

(Exact name of registrant as specified in its charter)

Florida ----- (State or Other Jurisdiction of Incorporation)	0-27937 ----- (Commission File Number)	65-0142474 ----- (IRS Employer Identification No.)
-----------------------------------------------------------------------	----------------------------------------------	-------------------------------------------------------------

1055 Hastings Street, Suite 1900 Vancouver, British Columbia ----- (Address of Principal Executive Offices)	V6E 2E9 ----- (Zip Code)
----------------------------------------------------------------------------------------------------------------------	--------------------------------

(604) 669-8817

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Section 2 - Financial Information

Item 2.02 Results of Operations and Financial Condition

Dragon Pharmaceutical Inc. announced its financial results for the first quarter of 2005 on the attached press release.

Edgar Filing: DRAGON PHARMACEUTICAL INC - Form 8-K

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibit No. -----	Exhibit Description -----
99	Press release announcing financial results for the first quarter of 2005.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

DRAGON PHARMACEUTICAL INC.,
a Florida Corporation

Dated: May 18, 2005

/s/ Maggie Deng

Maggie Deng
Chief Operating Officer

3

EXHIBIT INDEX

Exhibit No. -----	Description -----
99	Press release dated May 16, 2005 titled "Dragon Pharmaceutical Announces Financial Results for the First Quarter of 2005 with 65% Increase in Revenues from the prior year"

4